Senex Biotech's 'CX213' Receives FDA Fast Track Designation
Senex Biotech announced on August 7 that its candidate drug for the treatment of subarachnoid hemorrhage, 'CX213', has received Fast Track designation from the U.S. Food and Drug Administration (FDA).
The FDA Fast Track is a program that expedites the development and review of drug candidates that show the potential to address serious illnesses by overcoming the limitations of existing treatments or meeting unmet medical needs. Candidates designated for Fast Track status can engage in close communication with the FDA from the early stages of development, including early discussions on clinical trial design, development strategies, biomarkers, and regulatory strategies. At the application stage, they are eligible for rolling review, which allows the stepwise submission and review of completed portions of the application data. If related requirements are met, accelerated approval and priority review may also be granted.
CX213 is a cerium oxide nanozyme therapeutic developed independently by Senex Biotech using its proprietary 'Innosurface' platform technology. According to the company, CX213 is the world’s first cerium oxide nanozyme therapy to enter clinical trials. Designed as a first-in-class drug, it leverages the reactive oxygen species (ROS) scavenging ability of cerium oxide nanoparticles to target and suppress oxidative stress and neuronal cell damage that occur following subarachnoid hemorrhage. Current treatments for subarachnoid hemorrhage are focused on procedures and surgeries to block the ruptured cerebral aneurysm and the subsequent management of complications; there is currently no existing treatment targeting oxidative damage that occurs immediately after bleeding.
CX213 previously received FDA Orphan Drug Designation (ODD) last year, and now it has also secured Fast Track status. According to the company, the FDA reviewed the submitted documents in the course of the assessment with two rounds of additional queries, and granted Fast Track designation without requiring any changes to the underlying development rationale or direction.
Lee Seunghoon, CEO of Senex Biotech, stated, "This Fast Track designation is highly significant in that it represents the FDA’s official acknowledgment of CX213’s potential to address unmet medical needs in subarachnoid hemorrhage, as well as the necessity for its rapid development. We will accelerate subsequent clinical development so that we can deliver new treatment options to patients as quickly as possible."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Senex Biotech has completed Phase 1 clinical trials of CX213 based on the FDA Investigational New Drug (IND) approval and is currently preparing for Phase 2 trials. Following its selection for two large-scale projects from the Korea Drug Development Fund (KDDF) and successful Series B fundraising, the company plans to move forward with global clinical trials and pursue commercialization of CX213.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.